Gene therapies should be for all

Are healthcare systems prepared to deal with cost and accessibility of gene therapies on a global scale? More than 200 phase 2 and 3 gene therapy trials are currently underway, which could translate into up to 40 new products ’ being approved for clinical use in the next decade, and the potential eligibility of 1.09 million patients for this therapeutic modality in the next 15 years.

Read the source article at Nature
2021-08-12 01:00:00